GangCheng

Associate

Silicon Valley + 1.650.687.4155

Connect

Share

Gang Cheng represents start-up and emerging growth companies in a broad range of matters, including formation, general corporate, and venture capital financings. Gang also represents investors in venture capital financings and has experience in cross-border acquisition transactions.

Gang previously worked in the Silicon Valley and Shanghai offices of U.S. law firms. He has worked with clients in many industries, including semiconductor, biotechnology, software, e-commerce, and social media.

Erfahrung

  • Bristol Myers Squibb invests in Abata TherapeuticsJones Day advised Bristol Myers Squibb in its investment in Abata Therapeutics to support the development of its Treg cell therapy products.
  • Myeloma Investment Fund invests in Nammi Therapeutics, Inc.'s Series B financingJones Day advised Myeloma Investment Fund in $1 million investment in Nammi Therapeutics, Inc.'s Series B financing.
  • Konvu raises $5 million in Series A seed financingJones Day advised Konvu, a provider of application security solutions, in connection with its $5 million seed Series A financing.
  • Bristol Myers Squibb invests in Series B funding of NeoPhore Ltd.Jones Day advised Bristol Myers Squibb (NYSE: BMY) regarding investing in the Series B funding of NeoPhore Ltd.
  • GreatPoint Ventures invests in Coalesce.ioJones Day advised GreatPoint Ventures in the $50 million Series B financing of Coalesce.io, a data transformation company.
  • Bristol Myers Squibb participates in $75 million Series C financing of Accent TherapeuticsJones Day advised Bristol Myers Squibb Company in connection with the $75 million Series C financing of Accent Therapeutics, a biopharmaceutical company developing precision cancer therapies by targeting RNA-modifying proteins (RMPs), aiming to translate innovative science into transformative treatments for cancer patients.
  • GreatPoint Ventures leads $5 million funding of DatalogzJones Day advised GreatPoint Ventures in leading the $5 million funding of Datalogz, the pioneer in ending business intelligence (BI) sprawl across Fortune 500 enterprises.
  • Bristol Myers Squibb participates in $37 million financing of EvolveImmune TherapeuticsJones Day advised Bristol Myers Squibb in connection with the $37 million financing of EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents.
  • Orange invests in $60 million Series B funding of AiraloJones Day represented Orange, S.A. in connection with its participation in the $60 million Series B financing of Airalo, a company that uses software-based eSIM connectivity to provide a wide range of lower-cost mobile data packages for international travelers.
  • GreatPoint Ventures invests in NixtlaJones Day advised GreatPoint Ventures in its investment in Nixtla Inc., a startup that builds forecasting and time series software for data scientists and developers.
  • GreatPoint Ventures participates in $10.5 million Series B financing of HyporiJones Day advised GreatPoint Ventures in connection with the $10.5 million Series B financing of Hypori, an award-winning SaaS company transforming secure access to data and redefining zero-trust bring-your-own-device ("BYOD"), with no data at rest or in transit.
  • Accelmed Partners makes $35 million investment in SKNV Inc.Jones Day advised Accelmed Partners in its $35 million investment in SKNV Inc., a full continuum-of-care dermatology digital health company for in-practice dispensing and ecommerce of customized prescriptions and skincare.
  • CDPQ leads $125 million Series D financing of Soli OrganicJones Day advised CDPQ as lead investor in the $125 million Series D financing of Soli Organic, the nation's only soil-based, indoor farming company delivering 100% USDA certified organic produce.
  • Omnes Capital leads $10 million financing round of WhiteLab GenomicsJones Day represented Omnes Capital as a lead investor in connection with the $10 million financing round of WhiteLab Genomics, a Y-Combinator backed AI-powered predictive software simulation platform for the design of gene and cell therapies.
  • Fortanix raises $90 million in Series C Preferred Stock financingJones Day advised Fortanix Inc. in its $90 million Series C Preferred Stock financing.
  • GreatPoint Ventures invests in Current FoodsJones Day advised GreatPoint Ventures in its seed investment in Current Foods, a developer of plant-based seafood.
  • Hookit sells company to Kore SoftwareJones Day advised Hookit in the sale of 100% of Hookit’s stock to KORE Software, a portfolio company of Serent Capital.
  • Riverside portfolio company acquires AugusoftJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Modern Campus of Augusoft, a SaaS leader in enrollment management for continuing and corporate education programs.
  • Riverside portfolio company acquires Signal VineJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Modern Campus of Signal Vine, the higher education industry’s most impactful two-way text messaging platform.
    •

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.